U.S. Markets open in 3 hrs 54 mins
  • S&P Futures

    3,341.75
    -41.25 (-1.22%)
     
  • Dow Futures

    26,942.00
    -423.00 (-1.55%)
     
  • Nasdaq Futures

    11,481.00
    -107.00 (-0.92%)
     
  • Russell 2000 Futures

    1,561.10
    -27.90 (-1.76%)
     
  • Crude Oil

    38.08
    -1.49 (-3.77%)
     
  • Gold

    1,902.70
    -9.20 (-0.48%)
     
  • Silver

    24.38
    -0.19 (-0.77%)
     
  • EUR/USD

    1.1755
    -0.0035 (-0.2939%)
     
  • 10-Yr Bond

    0.7780
    0.0000 (0.00%)
     
  • Vix

    35.87
    +3.41 (+10.51%)
     
  • GBP/USD

    1.2972
    -0.0069 (-0.5306%)
     
  • USD/JPY

    104.2570
    -0.2370 (-0.2268%)
     
  • BTC-USD

    13,656.14
    -53.88 (-0.39%)
     
  • CMC Crypto 200

    268.90
    +7.61 (+2.91%)
     
  • FTSE 100

    5,630.29
    -98.70 (-1.72%)
     
  • Nikkei 225

    23,418.51
    -75.79 (-0.32%)
     

Has Champions Oncology (CSBR) Outpaced Other Medical Stocks This Year?

Zacks Equity Research
Zacks.com featured highlights include: Lululemon, Sirius, Kohl's and Olympic Steel
Zacks.com featured highlights include: Lululemon, Sirius, Kohl's and Olympic Steel

Investors focused on the Medical space have likely heard of Champions Oncology (CSBR), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of CSBR and the rest of the Medical group's stocks.

Champions Oncology is a member of our Medical group, which includes 817 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CSBR is currently sporting a Zacks Rank of #1 (Strong Buy).

The Zacks Consensus Estimate for CSBR's full-year earnings has moved 277.78% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

According to our latest data, CSBR has moved about 209.02% on a year-to-date basis. At the same time, Medical stocks have gained an average of 0.35%. This means that Champions Oncology is performing better than its sector in terms of year-to-date returns.

Looking more specifically, CSBR belongs to the Medical - Drugs industry, which includes 171 individual stocks and currently sits at #90 in the Zacks Industry Rank. Stocks in this group have lost about 6.53% so far this year, so CSBR is performing better this group in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track CSBR. The stock will be looking to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Champions Oncology, Inc. (CSBR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.